September 11, 2018: The AHA, Association of American Medical Colleges, America’s Essential Hospitals, 340B Health and three hospital systems today asked a federal court to order the Department of Health and Human Services to make effective within 30 days a final rule requiring drug companies to disclose the ceiling price for 340B outpatient drugs. Required by Congress in 2010, HHS has delayed the rule’s effective date five times. To ensure accuracy and compliance with the 340B drug savings program, the rule also describes how ceiling prices must be calculated and would allow the federal government to levy civil monetary penalties against drug companies that intentionally overcharge 340B providers.
Contact Your Senator on HELP Committee and Urge Them Not to Include 340B Provisions as Part of Legislative Package
The Senate Committee on Health, Education, Labor and Pensions has released the Lower Health Care Costs Act of 2019 – bipartisan discussion draft legislation to…
Joint Status Report and Stipulation of Dismissal Re: 340B Delayed Regulations on Transparency and CMPs
For more than 25 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
The AHA is pleased that, in response to our successful lawsuit, the Health Resources and Services Administration today launched a new website to shine needed…